Physician profile
Michael C Ott
NPI 1629052725
$909,083.62
in general payments reported to CMS, 2019-2025
12 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116K · 2020: $89K · 2021: $119K · 2022: $132K · 2023: $189K · 2024: $116K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $366K · Travel and Lodging: $71K · Food and Beverage: $10K · Consulting Fee: $5,850 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $365,625.00 |
| Travel and Lodging | $70,878.56 |
| Food and Beverage | $10,340.53 |
| Consulting Fee | $5,850.00 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $902,782.95 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $5,101.99 | 2019-2020 | |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.81 | 2019-2025 | Ofev, Jascayd |
| Vapotherm INC | $101.05 | 2020 | |
| Inspire Medical Systems, INC. | $33.92 | 2023 | Inspire |
| Gilead Sciences, INC. | $30.12 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.55 | 2023 | Dupixent |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.18 | 2022 | |
| Merck Sharp & Dohme LLC | $18.06 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.96 | 2025 | Lifevest |
| Boston Scientific Corporation | $14.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.